Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bronx, NY
NPI
1538245824
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3736 Henry Hudson Pkwy
Bronx, NY, 10463
Phone (718) 549-6268
Groups this clinician bills Medicare through
Medicare paid, 2024
$899K
44,686 services
Medicare patients, 2024
504
Average age 79
Drug cost, 2024
$2.4M
5,890 prescriptions
Company payments, 2025
$102K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Martin M Grajower was code J3111 (injection, romosozumab-aqqg, 1 mg), 18,900 times for 14 patients. In total Martin M Grajower billed 44,686 services in 57 codes, and Medicare paid $899K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 18,900 | 14 | $8.65 | $163K |
| J0897 Injection, denosumab, 1 mg | Office | 16,292 | 163 | $20.55 | $335K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,500 | 418 | $13.34 | $20K |
| 99214 Office E&M - Established | Office | 1,100 | 378 | $101.20 | $111K |
| 36415 Venipuncture Blood Collection | Office | 1,098 | 410 | $8.65 | $9,498 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 598 | 93 | $51.19 | $31K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 527 | 78 | $40.01 | $21K |
| 82947 Clinical Chemistry | Office | 477 | 166 | $3.85 | $1,836 |
| 81002 Clinical Chemistry | Office | 430 | 218 | $3.41 | $1,466 |
| 96372 Injection Administration | Office | 409 | 175 | $12.23 | $5,003 |
| 99212 Office E&M - Established | Office | 334 | 187 | $45.30 | $15K |
| 99213 Office E&M - Established | Office | 334 | 202 | $74.15 | $25K |
| 93000 Electrocardiogram | Office | 237 | 183 | $11.77 | $2,789 |
| 77085 Standard X-ray | Office | 202 | 202 | $58.38 | $12K |
| 76981 Ultrasound - Nonspecific | Office | 192 | 163 | $89.53 | $17K |
By year: 2022 $683K for 20,874 services; 2023 $696K for 24,539 services; 2024 $899K for 44,686 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,098 | 410 | $8.65 | $9,498 |
| 82947 Clinical Chemistry | 477 | 166 | $3.85 | $1,836 |
| 81002 Clinical Chemistry | 430 | 218 | $3.41 | $1,466 |
Medicare prescription drug claims, 2024
In 2024, the drug Martin M Grajower prescribed most often to Medicare patients was Rosuvastatin Calcium, with 379 prescriptions and refills. In total Martin M Grajower wrote 5,890 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 379 | 1,124 | 119 | $7,434 |
| Ozempic Semaglutide | 315 | 579 | 63 | $553K |
| Atorvastatin Calcium Generic | 275 | 781 | 80 | $4,827 |
| Pioglitazone Hcl Generic | 253 | 728 | 72 | $4,920 |
| Synthroid Levothyroxine Sodium | 243 | 651 | 63 | $27K |
| Mounjaro Tirzepatide | 218 | 328 | 34 | $350K |
| Losartan Potassium Generic | 207 | 583 | 58 | $3,024 |
| Metformin Hcl Generic | 182 | 536 | 54 | $1,904 |
| Jardiance Empagliflozin | 169 | 413 | 45 | $241K |
| Farxiga Dapagliflozin Propanediol | 165 | 391 | 43 | $212K |
| Trulicity Dulaglutide | 154 | 246 | 34 | $236K |
| Ezetimibe Generic | 132 | 388 | 43 | $4,379 |
| Spironolactone Generic | 127 | 347 | 43 | $1,515 |
| Metoprolol Succinate Generic | 110 | 325 | 36 | $2,272 |
| Eliquis Apixaban | 100 | 216 | 27 | $125K |
Brand drugs: 2,124 claims; generic drugs: 3,686 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Martin M Grajower $102K ($102K in general payments such as food, travel and fees) from 23 companies. The largest payer was Novo Nordisk Inc with $72K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 66 | $72K |
| Echosens North America, Inc. | 24 | $29K |
| Amgen Inc. AMGN | 7 | $178 |
| Ascendis Pharma Endocrinology Inc ASND | 8 | $175 |
| Madrigal Pharmaceuticals MDGL | 6 | $144 |
| Corcept Therapeutics CORT | 5 | $122 |
| Lilly USA, LLC LLY | 5 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $106 |
| Radius Health, Inc. | 4 | $100 |
| Abbott Laboratories ABT | 4 | $95.52 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.